Table 1

Statistics of monocyte analysis from SLE patients and healthy controls

Analysis SLE Donor p of SLE versus donor
PBM (day 0) (n=17) (10/7) (n=8)
CD1437.4%90.4 %<0.0001
range: 12–85.4%range: 79.2–97%
MFI 94MFI 2580.002
range: 5.2–47%range: 20.3–91.3%
MoAC (day 3) (n=12) (7/5) (n=6)
range: 0–37.8range: 21–88.9
range: 60.8–98range: 6.5–74
HLA-DRMFI 39MFI 900.022
MoDC (day 3) (n=6) (3/3) (n=6)
range: 16.1–35.2%range: 65.2–96.5%
range: 79.2–99.8%range: 44.3–71%
MFI 150MFI 430.0027
range: 61.4–96.6%range: 83.3–99.8%
MFI 317MFI 5240.081
TNFα (24 h) (n=23) (n=6)
MoAC (n=17) (10/7)4306 pg366 pg0.0004
range: 289–12 300range: 50–1202
MoDC (n=6) (3/3)1965 pg0.0150
range: 902–2566
  • Groups are listed according to the experimental setting (analysis). Data shown represent the relevant results where monocytic cells of SLE patients differ from monocytic cells of healthy donors. With the exception of HLA-DR on MoDC of SLE patients all differences listed are statistically significant (p<0.05). The number of active/inactive patients is given in parentheses. PBM, peripheral blood monocytes; MoAC, monocyte derived accessory cells (non-supplemented), TNFα, tumour necrosis factor α; MoDC, monocyte derived dendritic cells (GM-CSF and IL4 supplemented); MFI, mean fluorescence intensity.